Putting you at the centre of all decisions affecting your health
30% of the European population lives with allergies, asthma and COPD
Because breathing is taken for granted, we work for better recognition of chronic respiratory diseases

Our funding partners

EFA operates with funding from membership fees, public EU funding, private unrestricted core-funding and project funding from corporate sources and donations.

 

Our Annual Report

The Annual Report, including audited financial accounts and overall budget for the next year is approved by the Annual General Meeting of Members.

Here are the reports from 20132012201120102009200820072006 and 2005.

 

The total breakdown of funding is based on the 2013 annual accounts as follows:

Membership Fees:

€ 12,012

European Commission:                 

€ 86,864.66

Funding from Sustainable Industry Partnerships:

€508,000

   

5 Stars*****

 
GSK

€ 55,000

Novartis

€ 55,000

   

3 Stars***

 
ALK Abelló € 30,000
Almirall                 € 30,000
AirLiquide Healthcare € 30,000
Boehringer Ingelheim € 30,000
Boston Scientific € 30,000
Chiesi € 30,000
Stallergenes € 30,000
   

1 Star*

 
Vifor € 10,000
   

COPD Project:  

€ 63,000
Almirall                 € 15,000
AirLiquide Healthcare € 12,000
Boehringer Ingelheim € 12,000
Chiesi € 12,000
Novartis € 12,000
   

Allergy Awareness Project:

€ 50,000
ALK Abelló

€ 25,000

Stallergenes     

€ 25,000

   

Oxygen Project:

€ 50,000
AirLiquide Healthcare

€ 25,000

Almirall

€ 25,000

   

EU Training Project:

 € 15,000

 

 Novartis  € 15,000